Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Europe’s ‘Regulatory Lasagna’: Commission Facing Yet More AI Act Criticism

Executive Summary

Is regulating artificial intelligence a good idea? A lawyer questions whether the European Commission’s proposed AI Act is appropriate for medtech, where a growing “regulatory lasagna” could compound notified body capacity issues and SME workload.

You may also be interested in...



Regulators Need New Skills & Smarter Guidance To Govern AI, Says EMA Chief

A two-day workshop saw EU policymakers and regulators meet with dozens of representatives from the pharmaceutical, health and medtech industries to discuss the future of regulating AI in medicine and its uses in the medicinal product lifecycle.

Beyond MDR: How Stricter EU Rules On AI And Data Are Set To Impact Medtech

The second half of 2022 has seen much debate and concern from EU medtech stakeholders around numerous proposed horizontal rules that will affect digital products. Changes in policies around AI, cybersecurity and data-sharing are likely to be an even bigger theme in 2023.

EU Data Act Must Consider ‘Sectoral Peculiarities’ Says Medtech Industry

The European Commission’s proposed Data Act is among a growing pile of horizontal regulations set to impact the medtech industry. But changes should be made to protect trade secrets and other sector-specific nuances, MedTech Europe warns.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel